Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure

Habib, Mhd Baraa; Elshafei, Mohamed; Ali, Elrazi; Sardar, Sundus; Ali, Khaled M.; Haddad, Naim; Abdelaty, Mohamed

doi:10.1002/ccr3.4851

Cited by 2 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ESL‐induced hyponatremia (and CBZ‐ and OXC‐induced hyponatremia) is usually mild or moderate, asymptomatic, and rarely leads to discontinuation of therapy 4,5 . Hyponatremia lower than 125 mmol/L is seen in 1.5% of patients, and hyponatremia under 120 mmol/L is extremely rare during ESL treatment 5,7,8 …”

Section: Introductionmentioning

confidence: 99%

“… 4 , 5 Hyponatremia lower than 125 mmol/L is seen in 1.5% of patients, and hyponatremia under 120 mmol/L is extremely rare during ESL treatment. 5 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

“…4,5 Hyponatremia lower than 125 mmol/L is seen in 1.5% of patients, and hyponatremia under 120 mmol/L is extremely rare during ESL treatment. 5,7,8 There are a few risk factors for dibenzazepine-induced hyponatremia. For CBZ-and OXC-related hyponatremia, these risk factors are older age and concomitant use of a high-risk medication.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Eslicarbazepine‐induced hyponatremia: A retrospective single‐center real clinical practice study

Strýček,

Všianský,

Doležalová

et al. 2023

Epilepsia Open

View full text Add to dashboard Cite

Hyponatremia is a typical side effect of antiseizure drugs from the dibenzazepine family. The study investigated the prevalence of hyponatremia in patients with epilepsy who were treated with eslicarbazepine. We aimed to determine the prevalence of hyponatremia, reveal the factors leading to the discontinuation of treatment, and identify possible risk factors for the development of hyponatremia including the dose dependency. The medical records of 164 patients with epilepsy taking eslicarbazepine in our center were analyzed. The overall prevalence of hyponatremia was 30.5%. The prevalence of mild hyponatremia, seen in 14% to 20% of patients, was not dose dependent. The prevalence of moderate and severe hyponatremia was significantly dose dependent. The severity of hyponatremia was significantly dose dependent. Severe hyponatremia was found in 6.1% of patients. Hyponatremia was asymptomatic in the majority of cases, and in 48% did not require any management. Hyponatremia was the reason for discontinuation in 6.2% of patients. The major risk factor for developing hyponatremia was older age. The study shows that eslicarbazepine‐induced hyponatremia is usually mild and asymptomatic. It usually does not require any management and seldom leads to treatment discontinuation. Hyponatremia is dose dependent. Another major risk for developing hyponatremia (besides dose) is older age.

show abstract

Section: Introductionmentioning

confidence: 99%

“… 4 , 5 Hyponatremia lower than 125 mmol/L is seen in 1.5% of patients, and hyponatremia under 120 mmol/L is extremely rare during ESL treatment. 5 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%